SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Christensen Lars) srt2:(2005-2009)"

Search: WFRF:(Christensen Lars) > (2005-2009)

  • Result 1-10 of 10
Sort/group result
   
EnumerationReferenceCoverFind
1.
  •  
2.
  • Buunen, M, et al. (author)
  • COLOR II. A randomized clinical trial comparing laparoscopic and open surgery for rectal cancer.
  • 2009
  • In: Danish medical bulletin. - 1603-9629 .- 0907-8916. ; 56:2, s. 89-91
  • Journal article (peer-reviewed)abstract
    • INTRODUCTION: Laparoscopic resection of rectal cancer has been proven efficacious but morbidity and oncological outcome need to be investigated in a randomized clinical trial. Trial design: Non-inferiority randomized clinical trial. METHODS: The COLOR II trial is an ongoing international randomized clinical trial. Currently 27 hospitals from Europe, South Korea and Canada are including patients. The primary endpoint is loco-regional recurrence rate three years post-operatively. Secondary endpoints cover quality of life, overall and disease free survival, post-operative morbidity and health economy analysis. RESULTS: By July 2008, 27 hospitals from the Netherlands, Belgium, Germany, Sweden, Spain, Denmark, South Korea and Canada had included 739 patients. The intra-operative conversion rate in the laparoscopic group was 17%. Distribution of age, location of the tumor and radiotherapy were equal in both treatment groups. Most tumors are located in the mid-rectum (41%). CONCLUSION: Laparoscopic surgery in the treatment of rectal cancer is feasible. The results and safety of laparoscopic surgery in the treatment of rectal cancer remain unknown, but are subject of interim analysis within the COLOR II trial. Completion of inclusion is expected by the end of 2009. Trial registration: Clinicaltrials.gov, identifier: NCT00297791 (www.clinicaltrials.gov).
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  •  
7.
  • Christoffersen, Christina, et al. (author)
  • The signal peptide anchors apolipoprotein m in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma
  • 2008
  • In: Journal of Biological Chemistry. - 1083-351X. ; 283:27, s. 18765-18772
  • Journal article (peer-reviewed)abstract
    • Lipoproteins consist of lipids solubilized by apolipoproteins. The lipid-binding structural motifs of apolipoproteins include amphipathic alpha-helixes and beta-sheets. Plasma apolipoprotein (apo) M lacks an external amphipathic motif but, nevertheless, is exclusively associated with lipoproteins ( mainly high density lipoprotein). Uniquely, however, apoM is secreted to plasma without cleavage of its hydrophobic NH2-terminal signal peptide. To test whether the signal peptide serves as a lipoprotein anchor for apoM in plasma, we generated mice expressing a mutated apoM(Q22A) cDNA in the liver ( apoM(Q22A)-Tg mice (transgenic mice)) and compared them with mice expressing wild-type human apoM( apoM-Tg mice). The substitution of the amino acid glutamine 22 with alanine in apoMQ22A results in secretion of human apoM without a signal peptide. The human apoM mRNA level in liver and the amount of human apoM protein secretion from hepatocytes were similar in apoM-Tg and apoMQ22A-Tg mice. Nevertheless, human apoM was not detectable in plasma of apoMQ22A-Tg mice, whereas it was easily measured in the apoM-Tg mice. To examine the plasma metabolism, recombinant apoM lacking the signal peptide was produced in Escherichia coli and injected into wild-type mice. The apoM without signal peptide did not associate with lipoproteins and was rapidly cleared in the kidney. Accordingly, ligation of the kidney arteries in apoMQ22A-Tg mice resulted in rapid accumulation of human apoM in plasma. The data suggest that hydrophobic signal peptide sequences, if preserved upon secretion, can anchor plasma proteins in lipoproteins. In the case of apoM, this mechanism prevents rapid loss by filtration in the kidney.
  •  
8.
  • Johnsen, Nina Fans, et al. (author)
  • Physical activity and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort
  • 2009
  • In: International Journal of Cancer. - : Wiley. - 0020-7136 .- 1097-0215. ; 125:4, s. 902-908
  • Journal article (peer-reviewed)abstract
    • The evidence concerning the possible association between physical activity and the risk of prostate cancer is inconsistent and additional data are needed. We examined the association between risk of prostate cancer and physical activity at work and in leisure time in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. In our study, including 127,923 men aged 20-97 years from 8 European countries, 2,458 cases of prostate cancer were identified during 8.5 years of followup. Using the Cox proportional hazards model, we investigated the associations between prostate cancer incidence rate and occupational activity and leisure time activity in terms of participation in sports, cycling, walking and gardening; a metabolic equivalent (MET) score based on weekly time spent on the 4 activities; and a physical activity index. MET hours per week of leisure time activity, higher score in the physical activity index, participation in any of the 4 leisure time activities, and the number of leisure time activities in which the participants were active were not associated with prostate cancer incidence. However, higher level of occupational physical activity was associated with lower risk of advanced stage prostate cancer (p(trend) = 0.024). In conclusion, our data support the hypothesis of an inverse association between advanced prostate cancer risk and occupational physical activity, but we found no support for an association between prostate cancer risk and leisure time physical activity. (C) 2009 UICC
  •  
9.
  • Kristensen, Lars Erik, et al. (author)
  • The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.
  • 2007
  • In: Scandinavian Journal of Rheumatology. - : Informa UK Limited. - 1502-7732 .- 0300-9742. ; 36:6, s. 411-417
  • Journal article (peer-reviewed)abstract
    • Objective: To compare the efficacy of adalimumab, etanercept, and infliximab in patients with established rheumatoid arthritis (RA) taking concomitant methotrexate (MTX) by calculating the number needed to treat (NNT) using three different methods. Methods: A systematic literature search of the Cochrane Library, MEDLINE, and EMBASE was conducted from inception to 30 June 2006. Two pairs of investigators, a Danish and a Swedish pair, independently conducted a structured literature review. The reviewers selected any published randomized, double-blind, MTX controlled study of adalimumab, etanercept, and infliximab, presenting the American College of Rheumatology 50% response (ACR50) after 12 months in RA patients with a mean disease duration of at least 5 years. The two review groups independently extracted the estimates necessary to calculate the NNT. Results: The reviewers consistently selected the same three randomized, controlled trials (RCTs), one for each of the drugs, and extracted equal data for the number of patients completing the 12-month intervention, and the corresponding number of ACR50 responding patients after therapy. Some baseline differences were noted: patients in the etanercept trial had a shorter disease duration and did not receive MTX prior to inclusion; patients in the adalimumab study had lower Health Assessment Questionnaire (HAQ) scores. The calculated NNTs varied slightly depending on the method used. The fully adjusted NNTs (95% confidence intervals) for adalimumab, etanercept, infliximab standard dosage and infliximab double dosage were 4 (3-6), 4 (3-6), 8 (4-66), and 4 (3-11) patients, respectively. Conclusion: This study indicates equal efficacy of the three anti-tumour necrosis factor (TNF) therapies.
  •  
10.
  • Mørkeberg Krogh, Astrid, et al. (author)
  • Adaptation of Saccharomyces cerevisiae expressing a heterologous protein
  • 2008
  • In: Journal of Biotechnology. - 1873-4863 .- 0168-1656. ; :137, s. 28-33
  • Journal article (peer-reviewed)abstract
    • Production of the heterologous protein, bovine aprotinin, in Saccharomyces cerevisiae was shown to affect the metabolism of the host cell to various extent depending on the strain genotype. Strains with different genotypes, industrial and laboroatory, respectively, were investigated. The maximal specific growth rate of the strains was reduced by 54% and 33%, respectively, upon the introduction of the gene encoding aprotinin. Growing the strains in sequential shake flask cultivations for 250 generations led to an increased maximal specific growth rate and a decrease in the yield of aprotinin as a result of the adaptation. Determination of the level of mRNA encoding aprotinin and the plasmid copy number pointed to different mechanisms responsible for the decline in aprotinin yield in the different strains.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-10 of 10
Type of publication
journal article (6)
reports (2)
conference paper (1)
book chapter (1)
Type of content
peer-reviewed (7)
other academic/artistic (2)
pop. science, debate, etc. (1)
Author/Editor
Dahlbäck, Björn (2)
Ahnström, Josefin (2)
Axler, Olof (2)
Christoffersen, Chri ... (2)
Kim, S. H. (1)
Rohrmann, Sabine (1)
show more...
Overvad, Kim (1)
Kaaks, Rudolf (1)
Trichopoulou, Antoni ... (1)
Tumino, Rosario (1)
Sánchez, Maria-José (1)
Manjer, Jonas (1)
Wirfält, Elisabet (1)
Khaw, Kay-Tee (1)
Wareham, Nick (1)
Key, Timothy J (1)
Riboli, Elio (1)
Geborek, Pierre (1)
Påhlman, Lars (1)
Egevad, Lars (1)
Olsson, Lisbeth, 196 ... (1)
Kartus, Jüri, 1955 (1)
Pala, Valeria (1)
Rinaldi, Sabina (1)
Allen, Naomi E (1)
Bueno-de-Mesquita, H ... (1)
Tjonneland, Anne (1)
González, Carlos A (1)
Boffetta, Paolo (1)
Matthiessen, P. (1)
Johansson, Margareta (1)
Sernert, Ninni, 1954 (1)
Ejerhed, Lars, 1951 (1)
Maria Huerta, Jose (1)
Huntley, Brian (1)
Lahmann, Petra H (1)
Misirli, Gesthimani (1)
Kiemeney, Lambertus ... (1)
Møller, Kasper (1)
Haglind, Eva, 1947 (1)
Cuesta, M A (1)
Jess, P (1)
Rosenberg, J (1)
Bonjer, H J (1)
Saxne, Tore (1)
Björn, Lars Olof (1)
Bulut, O. (1)
Chapin III, F.S. (1)
Christensen, Torben (1)
Bliddal, H. (1)
show less...
University
Lund University (5)
University of Gothenburg (2)
Uppsala University (2)
Chalmers University of Technology (1)
Karlstad University (1)
Karolinska Institutet (1)
Language
English (8)
Swedish (2)
Research subject (UKÄ/SCB)
Medical and Health Sciences (5)
Natural sciences (1)
Engineering and Technology (1)
Social Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view